Qiagen N v achieved in the fourth quarter 2025, above Company average Revenue improvement of 6% year on year, to $ 2,034.50 millions.
Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 48 other companies have achieved higher Revenue growth. While Qiagen N V ' s Revenue increase of 6% ranks overall at the positon no. 2309 in the fourth quarter 2025.
Qiagen N V 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Dec 31 2025)
12 Months Ending (Dec 31 2024)
12 Months Ending (Dec 31 2023)
12 Months Ending (Dec 31 2022)
12 Months Ending (Dec 31 2021)
Cumulative Revenue 12 Months Ending
$ 2,034.50
$ 1,919.35
$ 1,900.69
$ 2,081.04
$ 2,985.38
Y / Y Revenue Growth (TTM)
6 %
0.98 %
-8.67 %
-30.29 %
59.62 %
Year on Year Revenue Growth Overall
Ranking
# 3014
# 3523
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
6 %
0.98 %
-8.67 %
-30.29 %
59.62 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 3014
# 3523
# 0
# 0
# 0
Cumulative Revenue growth Comment
Although Qiagen N V 's Annual Revenue growth year on year were below company's average 8.89% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6% year on year, from 0.98% in Dec 31 2024.
In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3014, from total ranking in previous quarter at 3523.
Although Qiagen N V 's Annual Revenue growth year on year were below company's average 8.89% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 6% year on year, from 0.98% in Dec 31 2024.
In the Healthcare sector 406 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3014, from total ranking in previous quarter at 3523.
About Qiagen N V Revenue Growth Rates (QGEN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
10.26%